OM
Opaleye Management Portfolio holdings
AUM
$494M
This Quarter Return
+25.54%
1 Year Return
+68.17%
3 Year Return
+608.37%
5 Year Return
+807.76%
10 Year Return
+24,567.29%
AUM
$135M
AUM Growth
+$135M
(+6.3%)
Cap. Flow
+$13.8M
Cap. Flow
% of AUM
10.23%
Top 10 Holdings %
Top 10 Hldgs %
69.24%
Holding
34
New
11
Increased
9
Reduced
7
Closed
4
Top Buys
| 1 |
Travere Therapeutics
TVTX
|
$24.4M |
| 2 |
CMRX
Chimerix, Inc.
CMRX
|
$12.2M |
| 3 |
GNMK
GenMark Diagnostics, Inc
GNMK
|
$4.32M |
| 4 |
BIND
BIND THERAPEUTICS INC
BIND
|
$3.25M |
| 5 |
InspireMD
NSPR
|
$3.1M |
Top Sells
| 1 |
GENT
GENTIUM SPA ADS
GENT
|
$29.2M |
| 2 |
Ligand Pharmaceuticals
LGND
|
$3.7M |
| 3 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
$3.64M |
| 4 |
Geron
GERN
|
$3.22M |
| 5 |
Nuwellis
NUWE
|
$2.13M |
Sector Composition
| 1 | Healthcare | 72.57% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Travere Therapeutics
TVTX
$1.56B
| $24.4M | 18.06% | +1,153,230 | New | +$24.4M |
|
|
ARIA
2
DELISTED
Ariad Pharmaceuticals Inc
ARIA
| $13.5M | 9.94% | 1,670,000 | – | – |
|
|
CMRX
3
DELISTED
Chimerix, Inc.
CMRX
| $12.2M | 9.04% | +536,000 | New | +$12.2M |
|
|
PCYC
4
DELISTED
PHARMACYCLICS INC
PCYC
| $11.5M | 8.51% | 115,000 -5,000 | -4% | -$501K |
|
|
5
InspireMD
NSPR
$102M
| $6.56M | 4.85% | 2,150,000 +1,015,600 | +90% | +$3.1M |
|
6
Omeros
OMER
$283M
| $6.04M | 4.46% | 500,100 +40,100 | +9% | +$484K |
|
|
CEMP
7
DELISTED
Cempra, Inc.
CEMP
| $5.54M | 4.1% | 480,000 +115,000 | +32% | +$1.33M |
|
|
BIND
8
DELISTED
BIND THERAPEUTICS INC
BIND
| $5.11M | 3.77% | 427,000 +272,000 | +175% | +$3.25M |
|
|
NPSP
9
DELISTED
NPS PHARMACEUTICALS INC
NPSP
| $4.49M | 3.32% | 150,000 -55,000 | -27% | -$1.65M |
|
|
GNMK
10
DELISTED
GenMark Diagnostics, Inc
GNMK
| $4.32M | 3.19% | +435,000 | New | +$4.32M |
|
|
CSII
11
DELISTED
Cardiovascular Systems, Inc.
CSII
| $4.29M | 3.17% | 135,000 | – | – |
|
|
NVDQ
12
DELISTED
Novadaq Technologies Inc.
NVDQ
| $4.12M | 3.04% | 167,600 | – | – |
|
13
Standard BioTools
LAB
$481M
| $3.97M | 2.93% | 90,000 -42,500 | -32% | -$1.87M |
|
|
BLRX
14
BioLineRX
BLRX
$16.2M
| $3.24M | 2.39% | 1,451,000 +738,000 | +104% | +$1.65M |
|
15
Catalyst Pharmaceutical
CPRX
$2.52B
| $3.12M | 2.3% | 1,378,584 +24,684 | +2% | +$55.8K |
|
|
EPZM
16
DELISTED
Epizyme, Inc
EPZM
| $2.63M | 1.94% | +115,500 | New | +$2.63M |
|
|
17
Ligand Pharmaceuticals
LGND
$3.15B
| $2.35M | 1.74% | 35,000 -55,000 | -61% | -$3.7M |
|
|
18
Geron
GERN
$893M
| $2.3M | 1.7% | 1,100,000 -1,540,000 | -58% | -$3.22M |
|
|
FLXN
19
DELISTED
Flexion Therapeutics, Inc.
FLXN
| $2.23M | 1.65% | +135,500 | New | +$2.23M |
|
20
Evoke Pharma
EVOK
$8.49M
| $1.96M | 1.44% | +233,400 | New | +$1.96M |
|
|
CELGZ
21
DELISTED
Celgene Corporation Contingent Value Rights
CELGZ
| $1.88M | 1.39% | 660,000 -140,000 | -18% | -$399K |
|
|
TTPH
22
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
| $1.76M | 1.3% | 160,000 +6,500 | +4% | +$71.4K |
|
|
KBIO
23
DELISTED
KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE)
KBIO
| $1.47M | 1.09% | 545,000 +260,000 | +91% | +$703K |
|
|
ARRY
24
DELISTED
Array Biopharma Inc
ARRY
| $1.43M | 1.06% | +305,000 | New | +$1.43M |
|
25
Codexis
CDXS
$246M
| $1.43M | 1.05% | +698,300 | New | +$1.43M |
|